MED4抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P08903(MED4 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08903(MED4 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

MED4 antibody targets the MED4 subunit (also known as mitochondrial complex I subunit MED4 or NDUFA4) of mitochondrial complex I (NADH:ubiquinone oxidoreductase), a critical enzyme in the electron transport chain. This complex facilitates oxidative phosphorylation, driving ATP production by transferring electrons from NADH to ubiquinone. MED4 is a nuclear-encoded structural component integral to complex I assembly and stability. Its dysfunction is linked to mitochondrial disorders, such as Leigh syndrome, encephalopathy, and myopathies, often caused by mutations in mitochondrial DNA or nuclear genes encoding complex I subunits.

The MED4 antibody is widely used in research to study mitochondrial respiratory chain defects, cellular energy metabolism, and disease mechanisms. It aids in detecting MED4 protein expression via Western blotting, immunohistochemistry, or immunofluorescence, helping assess complex I integrity in tissues or cultured cells. Commercial MED4 antibodies are typically raised in rabbits or mice, validated for specificity across human and model organisms (e.g., mice, rats). Recent studies employ this antibody to explore metabolic reprogramming in cancer, neurodegeneration, and aging, where mitochondrial dysfunction plays a key role. Its application extends to evaluating therapeutic interventions targeting mitochondrial energy pathways.